- Home
- AMN vs ABUS Comparison
AMN vs ABUS Comparison
Compare AMN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMN | ABUS |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.6M | 815.5M |
| IPO Year | 2001 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AMN | ABUS |
|---|---|---|
| Price | $19.58 | $4.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $22.25 | $5.00 |
| AVG Volume (30 Days) | 974.4K | ★ 2.5M |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.58 | ★ 55.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,988,454,000.00 | $14,083,000.00 |
| Revenue This Year | $17.27 | N/A |
| Revenue Next Year | N/A | $783.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.53 | ★ 128.21 |
| 52 Week Low | $14.97 | $2.71 |
| 52 Week High | $24.72 | $5.10 |
Technical Indicators
Market Signals| Indicator | AMN | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 52.28 |
| Support Level | $17.85 | $4.19 |
| Resistance Level | $21.35 | $4.76 |
| Average True Range (ATR) | 0.88 | 0.22 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 59.08 | 49.65 |
Price Performance
Historical ComparisonAbout AMN AMN Healthcare Services Inc
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. A majority of its revenue is generated from the Nurse and Allied Solutions segment, which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.